论文部分内容阅读
Two years rituximab maintenance vs.observation after first-line treatment with bendamustine plus rit
【作 者】
：
【机 构】
：
Universitaetsklinik,Giessen,Germany Centre for Ha
【出 处】
：
2016年临床肿瘤学新进展学术研讨会
【发表日期】
：
2016年5期
其他文献
Baseline quality of life(QOL)as a predictor of stopping chemotherapy early,and of overall survival,i
会议
Crenolanib besylate,a type Ⅰ pan-FLT3 inhibitor,to demonstrate clinical activity in multiply relapse
会议
Final results of a phase Ⅲ randomized trial of CPX-351 versus 7+3 in older patients with newly diagn
会议
Phase Ⅲ non-inferiority study of cabazitaxel(C)20 mg/m2(C20)versus 25 mg/m2(C25)in patients(pts)with
会议
会议
A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage nonbulky Hodg
会议
Treatment-free remission(TFR)in patients(pts)with chronic myeloid leukemia in chronicphase(CML-CP)tr
会议
Randomized phase Ⅲ study on the effect of early intensification of rituximab in combination with 2-w
会议